Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
52 巻, 24 号
選択された号の論文の31件中1~31を表示しています
ORIGINAL ARTICLES
  • Xu-Feng Guo, Jun Wang, Shi-Jie Yu, Jia Song, Meng-Yao Ji, Ji-Xiang Zha ...
    2013 年 52 巻 24 号 p. 2693-2699
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective The aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 1B (ADH1B) genes have been implicated in the development of colorectal cancer (CRC). However, the results are inconsistent. In this study, a meta-analysis was performed to assess the associations between the ALDH2 and ADH1B polymorphisms and the risk of CRC.
    Methods Relevant studies were identified using PubMed, Web of Science and CNKI up to February, 2013. The pooled odds ratio (OR) with a 95% confidence interval (CI) was calculated using the fixed- or random-effects model.
    Results A total of 11 case-controlled studies were selected. Of these, 11 studies included 2,893 cases and 3,817 controls concerning the ALDH2 Glu487Lys polymorphism and six studies included 1,864 cases and 3,502 controls concerning the ADH1B polymorphism. The results indicated that there was a statistically significant link between the ALDH2 polymorphism and the risk of CRC (Glu/Lys+Lys/Lys vs. Glu/Glu: OR=0.87, 95%CI: 0.78-0.96, p=0.10; Glu/Lys vs. Glu/Glu: OR=0.87, 95%CI: 0.77-0.97, p=0.38); however, no significant associations were observed between the ADH1B polymorphism and the risk of CRC win any of the genetic models.
    Conclusion This meta-analysis demonstrated that the ALDH2 polymorphism, but not the ADH1B polymorphism, significantly increases the risk of CRC in East Asians.
  • Akira Sato, Michio Sata, Kenji Ikeda, Takashi Kumada, Namiki Izumi, Ya ...
    2013 年 52 巻 24 号 p. 2701-2706
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective We attempted to elucidate the clinical features of chronic hepatitis C patients who develop hepatocellular carcinoma (HCC) after achieving a sustained viral response (SVR) to interferon (IFN) therapy.
    Methods The clinical features of 130 patients at 19 hospitals who developed HCC after obtaining an SVR were retrospectively reviewed.
    Results Overall, 107 (82%) of the 130 patients were men, with 92 (71%) being ≥60 years of age and 76, 38 and 16 developing HCC within 5, 5-10 and 10-16.9 years after IFN therapy, respectively. Before receiving IFN therapy, 92 (71%) patients had cirrhosis and/or a low platelet count (<15×104 cells/μL). Lower albumin (<3.9 g/dL) and higher alpha fetoprotein (AFP) (≥10 ng/mL) levels were identified in a multivariate analysis to be independent variables of the development of HCC within five years after IFN therapy. Among 4,542 SVR patients, HCC occurred in 109 (2.4%) during a 5.5-year follow-up period, thus resulting in an occurrence rate of 4.6% for men and 0.6% for women.
    Conclusion SVR patients with lower albumin or higher AFP levels require careful assessments to prevent early HCC development after IFN therapy. HCC occurrence within >10 years of IFN therapy is not uncommon, and the risk factors remain uncertain, thus suggesting that all SVR patients should undergo long-term follow-up examinations for HCC development.
  • Eiji Oda
    2013 年 52 巻 24 号 p. 2707-2713
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    電子付録
    Objective Both increased serum levels of low-density lipoprotein cholesterol (LDLC) and metabolic syndrome (MetS) are associated with obesity and have been established to be risk factors of cardiovascular disease. However, studies on the relationship between LDLC and MetS have been limited.
    Methods Cross-sectional (n=3,871) and longitudinal (n=2,558) associations between LDLC and MetS were examined in a Japanese health screening population.
    Results The odds ratio (OR) [95% confidence interval (CI)] of coexisting MetS for each one SD increase in the LDLC level was 1.25 [1.12-1.40] (p<0.001) adjusted for body mass index (BMI) and other confounding covariates and 1.12 [0.97-1.28] (p=0.119) adjusted for numerical values of the components of MetS and other confounding covariates. The similarly adjusted ORs [95% CIs] for the highest quartile of LDLC (Q4) compared with the lowest quartile (Q1) were 1.76 [1.22-2.54] (p=0.002) and 1.46 (0.93-2.30) (p=0.101), respectively. The hazard ratio (HR) [95% CI] for developing MetS for each one SD increase in the LDLC level was 1.24 [1.10-1.40] (p<0.001) adjusted for BMI and other confounding covariates and 1.19 [1.05-1.34] (p=0.006) adjusted for the pre-existing dichotomous five components of MetS and other confounding covariates. The similarly adjusted HRs [95% CIs] for developing MetS for Q4 compared with Q1 were 1.71 [1.17-2.51] (p=0.006) and 1.61 [1.08-2.40] (p=0.020), respectively.
    Conclusion The LDLC level is associated with coexisting MetS and functions as a predictor of the development of MetS, independent of BMI or the pre-existing components of MetS, in a Japanese health screening population.
  • Ban Liu, Wenliang Che, Hongwei Yan, Weidong Zhu, Hongbao Wang
    2013 年 52 巻 24 号 p. 2715-2719
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective Statins prevent cardiovascular events in patients with coronary artery disease (CAD). However, there is little information regarding the vascular effects of statins on arterial wall stiffness in CAD patients.
    Methods A total of 36 patients were randomly assigned to receive rosuvastatin (10 mg per day) or simvastatin/ezetimibe (10/10 mg per day) for eight weeks. The aim of the present study was to determine the effects of rosuvastatin or simvastatin/ezetimibe on arterial wall stiffness measured according to the brachial and ankle pulse wave velocity (baPWV) in CAD patients.
    Results Both treatments significantly improved the levels of total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) (p<0.05). The ROCK activity and baPWV were significantly improved in the rosuvastatin group compared with that observed in the simvastatin/ezetimibe group (p<0.05). The changes in baPWV were significantly correlated with the changes in the ROCK activity (r=0.488, p<0.01), but not with the changes in the lipid profile or the hs-CRP level.
    Conclusion Compared with simvastatin/ezetimibe (10/10 mg), rosuvastatin (10 mg) appears to more effectively improve arterial wall stiffness that may be mediated by modulation of the ROCK activity.
  • Tomoko Hashimoto, Ai Morita, Yo Hashimoto, Fukuko Yagami, Kazutaka Sak ...
    2013 年 52 巻 24 号 p. 2721-2726
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective To investigate the seasonal variation of severe hypoglycemia in hospitalized elderly patients.
    Methods Among the patients hospitalized in our department between 2004 and 2010, we analyzed the records of 67 patients who required emergency admission for severe hypoglycemia and were aged 60 years or older. Comparisons were made between those admitted during the warm season (April-September) and those in the cold season (October-March).
    Patients The mean age of the 67 patients was 76±8 years, including 45 men and 22 women. Twenty-four patients were admitted in the warm season and 43 patients were admitted in the cold season, with the average annual number being 3.4±1.9 and 6.1±2.8, respectively (p<0.05).
    Results Admissions for patients taking insulin showed no significant difference between the warm and cold season. In contrast, significantly fewer patients taking oral hypoglycemic agents were admitted in the warm season than in the cold season (5 vs. 22, p<0.05). Among them, 26 patients (96%) were taking sulfonylurea, and anorexia associated with acute infections was the main cause of severe hypoglycemia. In the warm season, all of the patients were discharged without complications, while 8 patients had complications in the cold season.
    Conclusion A seasonal variation regarding hospitalization was observed for severe hypoglycemia among the patients 60 years of age or older, with a higher incidence in the cold season than the warm season, and anorexia related to infections in patients taking sulfonylureas was responsible for this variation. Accordingly, careful management of acute illness is needed for patients using sulfonylureas, especially during the cold season.
  • Takuma Isshiki, Tetsuo Yamaguchi, Yoshihito Yamada, Keita Maemura, Kos ...
    2013 年 52 巻 24 号 p. 2727-2732
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective Methotrexate (MTX) is a cytotoxic agent that is commonly employed as an alternative to corticosteroids to treat sarcoidosis, although the proper use and efficacy of MTX as a single agent remain unclear.
    Methods The clinical records of patients newly diagnosed with sarcoidosis who were admitted to our institution between 2000 and 2009 were reviewed. Among these patients, 26 received 7.5 mg of MTX per week as a single agent, and the independent effects of MTX were analyzed.
    Results Six of the 26 patients (23%) exhibited an improvement of sarcoidosis-related lesions. The skin lesions demonstrated a relatively higher response rate (37%) than the pulmonary lesions (9%). Ten of the 26 patients (39%) experienced adverse effects, mostly mild hepatotoxicity. No severe adverse effects, including irreversible hepatotoxicity, were observed.
    Conclusion Although the efficacy of low-dose MTX monotherapy for sarcoidosis in this study was not high (23%), some patients exhibited definite improvements, and the drug proved to be safe, suggesting its possible benefits as a single agent for treating sarcoidosis.
  • Masato Asahina, Kenji Sano, Yoshikatsu Fujinuma, Satoshi Kuwabara
    2013 年 52 巻 24 号 p. 2733-2737
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective The autoimmune mechanism is considered to play an important role in the development of acquired idiopathic generalized anhidrosis (AIGA), and muscarinic M3 receptors (M3Rs) on eccrine glands are possible autoimmune targets. We investigated the existence of autoantibodies against M3Rs in AIGA patients.
    Methods We immunostained M3R-expressing cultured cells with the serum of 12 AIGA patients (mean age: 35.0±11.7 years, mean disease duration: 26.6±25.8 months) and 10 healthy subjects (mean age: 32.4±10.4 years).
    Results The surface of the M3R-expressing cells was stained by the serum obtained from one of the 12 AIGA patients but not by the serum obtained from the remaining 11 patients or healthy subjects.
    Conclusion The presence of M3R autoantibodies may therefore be related to the underlying mechanism of disease in a subset of AIGA patients.
  • Fatma Alibaz-Oner, Meryem Can, Birkan Ilhan, Özge Polat, Gonca Mu ...
    2013 年 52 巻 24 号 p. 2739-2742
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective Data regarding the frequency of fibromyalgia (FM) in patients with Takayasu's arteritis (TAK) have not been previously reported. We aimed to investigate the frequency of FM in TAK, defined according to the new 2010 ACR Preliminary Diagnostic Criteria for Fibromyalgia. The association between the ACR-1990 and 2010 FM criteria and the effects of patient-reported outcomes (PROs) on FM were also analyzed.
    Methods We studied 55 patients (age: 42,30±12,37 years, F/M: 49/6) with TAK and 40 age- and sex-matched controls (age: 41±10.84 years, F/M: 31/9). All patients were examined for FM tender points by two observers and asked to complete the ACR 2010 FM questionnaire for FM. The SF-36, the Health Assessment Questionnaire (HAQ) and hospital anxiety and depression scales (HADS) were used to assess the quality of life. Thirty patients were reevaluated six months later.
    Results Seven (12.7%) patients with TAK and four patients with HC (10%) fulfilled the 2010 FM criteria (p=0.682), while three (5.4%) TAK patients and no controls (0%) met the 1990 criteria (p=0.133). FM was found at a significantly higher rate in the active patients than in the inactive patients according to the ACR-2010 FM criteria (p=0.006). The SF-36 physical component scores were significantly lower (p=0.003) and the HAQ scores were significantly higher in the TAK (p=0.006) patients than in the controls.
    Conclusion The frequency of FM is similar between the general population and patients with TAK. However, the incidence of FM is significantly higher in active patients. The new FM criteria subscales (WPI, SSS) are significantly correlated with scales such as the SF-36, anxiety and depression scales and HAQ in TAK patients, suggesting that, in a minority of patients with FM and TAK, PROs may be affected by the presence of FM.
  • Nobuko Hazeki, Kazuyuki Kobayashi, Haruko Shinke, Masatsugu Yamamoto, ...
    2013 年 52 巻 24 号 p. 2743-2748
    発行日: 2013年
    公開日: 2013/12/15
    ジャーナル オープンアクセス
    Objective Adverse skin reactions as a local side effect of nicotine patches sometimes interfere with smoking cessation therapy. We studied the effects of semipermeable membrane dressings (SMD) used under nicotine patches (NP) on nicotine absorption, as assessed according to the urinary cotinine levels, and skin symptoms.
    Methods First, the urinary cotinine levels were compared in eight nonsmokers that applied NP over SMD and NP without SMD (Study 1). The urinary cotinine levels were measured using a highly sensitive competitive enzyme immunoassay. Second, 28 subjects undergoing NP therapy for diagnosed nicotine dependence were randomly assigned into two groups in a crossover design to receive NP over SMD and NP without SMD. The urinary cotinine levels and skin symptoms were compared between the two treatment groups. During the follow-up period of 48 weeks, the smoking cessation rate was evaluated (Study 2).
    Results No statistical differences were observed in the urinary cotinine levels between the NP over SMD and NP without SMD groups. In Study 2, the skin symptoms improved with the use of SMD in 42.8% (6/14) of the patients and worsened in 28.5% (4/14) of the patients. No serious skin disorders were reported. The subjects followed in Study 2 exhibited smoking cessation rates of 92.8%, 78.5% and 64.2% at 12, 24 and 48 weeks, respectively.
    Conclusion The use of NP over SMD is a safe and effective alternative application to NP treatment for preventing the skin symptoms caused by NP without interfering with nicotine absorption.
CASE REPORTS
PICTURES IN CLINICAL MEDICINES
feedback
Top